Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Striverdi Respimat for the Maintenance Treatment of COPD

Drug Name (Brand/Generic)

Striverdi Respimat (olodaterol)

Company/Licensee

Boehringer Ingelheim Pharmaceuticals

Product Description

Inhaled beta2- adrenergic agonist (LABA)

Current Indication

Maintenance Treatment of COPD

Market Sector

Respiratory diseases

Development Status

Approved in the US, Europe and Canada
Expand

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top